CAS: 2230490-29-4; Tinengotinib
- 英文名称Tinengotinib
- 中文名称4-(5-(2-氯苯基)-3-甲基-2,10-二氢吡唑并[4,3-B]B[4,3-E][1,4]H-8-基)吗啉
- IUPAC名称4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b]pyrido[4,3-e][1,4]diazepin-8-yl)morpholine
- CAS编号2230490-29-4
- FDA UNII编号:WZ9TJ0L9Y8
- 分子式:C20H19ClN6O分子量:394.87
- 产品CID: 1157080
- 产品分类JAK/STAT Signaling → JAK | Protein Tyrosine Kinase/RTK → c-FMS | Protein Tyrosine Kinase/RTK → VEGFR | Inhibitors/Agonists → Cell Cycle → Aurora Kinase | Protein Tyrosine Kinase/RTK → FGFR
物理性质
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2902300000-甲苯
2903919090-氯苯
2909110000-乙醚
2922110001-单乙醇胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:CN-113620949-B
优先权日:2020-05-08
标 题 :Synthesis method of antitumor compound and intermediate thereof
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Ni S, Li L, Sun X, Wang Y, Yu Q, Wang W, Gu Z, Yu Z, Wu D, Wu F, Jiang S, Peng P. In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors. Eur J Pharm Sci. 2024 Jan 1;192:106658. doi: 10.1016/j.ejps.2023.106658. Epub 2023 Dec 2. 22(2):205-214. doi: 10.1158/1535-7163.MCT-22-0012.
📝 需求与反馈
尽可能描述清楚需求与问题信息
